Couple running the length of Hadrian's Wall to raise money for two charities
A London couple are running the length of Hadrian's Wall over five days to raise money for two charities that are close to their hearts.
Daniel and Amy Tarshish are undertaking the 137 kilometre trek from Bowness-on-Solway to Wallsend to raise money for Alzheimer's Research UK and The OppO Foundation.
Neither Amy nor Daniel are strangers to running long distances however running the equivalent of a half marathon everyday for five days with their gear on their back presents a different kind of challenge.
But, they are both passionate about the causes they are supporting and the impact that fundraising will have on the lives of many people across the country.
Daniel said: "Anybody who gives is making a difference for everybody else.
"This is not about us, it's not about our friends and family, it's about the people who will benefit from the work that the charities do."
Amy's mum passed away at 61-years-old from frontotemporal dementia which took her from vivacious person full of energy to someone who could barely swallow her food in just two years.
They are keen to raise money for a charity that is working to make a difference for people like Amy's mum - and for everyone else who is at risk of developing Alzheimer's.
Shortly before setting off on their journey former Prime Minister David Cameron, who is the President of Alzheimer's Research UK, got in touch to wish them good luck.
Daniel added: "It's such a criminal thief of a disease and it's something that you can't really defend against.
"You can do all the brain training and all that stuff that can keep your mind sharp, but if Alzheimer's decides it wants to get you, it will get you."
Daniel is raising money for The OppO Foundation, of which he is a trustee, a charity that supports military veterans who have suffered life changing injuries by providing them with physical equipment to help them participate in different sports.
The charity helps veterans rebuild their confidence by giving them a sense of purpose.
At the last Invictus Games, the charity provided every British athlete with something that would enable them to participate, such as a titanium wheelchair, or something a little bit extra just to help them.
"The service personnel for this country have done so much in the service of the nation," he said.
"And they do it not just for their friends and family, they do it for people they don't know. They do it for the whole nation.
"To sacrifice yourself or parts of yourself, if you like, for people that you don't know, that is really quite special."
You can support Amy via JustGiving and Daniel via JustGiving.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Explore dementia care resources at The Bridge in Shreveport
SHREVEPORT, La. (KTAL/KMSS) – The Bridge Alzheimer's & Dementia Resource Center invites the community to open house tours every other Tuesday. The tours will allow guests to learn about The Bridge's programs, meet the team, and delve into its available services supporting caregivers and individuals living with Alzheimer's and other dementias in the region. CHRISTUS highlights speech therapy for communication disorders Guests will also be able to see The Bridge Adult Day Center, Northwest Louisiana's first dementia-centered adult day program. This program provides individuals with dementia with a safe, inviting environment while caregivers relax and refresh. 'We want people to know that they're not alone,' said Toni Goodin, Executive Director of The Bridge Alzheimer's & Dementia Resource Center. 'These tours are a simple way for anyone—whether a caregiver, family member, or healthcare provider—to come see what we offer and ask questions in a relaxed, welcoming setting.' The first tour will take place on Tuesday, June 3, from 1:30 p.m. to 3:30 p.m. Registration is not required. For more information, visit The Bridge during tour hours. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
New York Post
11 hours ago
- New York Post
Slash your stress by 65% — and in just 8 minutes — with this dreamy fix to ‘calm your brain,' neurologist says
Take aurally. Turns out the ultimate anxiety remedy may not be in your medicine cabinet — but on Spotify. An eight-minute ambient track called 'Weightless' by British band Marconi Union is being hailed as the musical equivalent of a chill pill. 3 The track, 'Weightless' by Marconi Union (above) — cooked up with sound therapists to melt stress — actually works, according to science. Just Music The song was actually designed to de-stress listeners — and science says it works. In a study by Mindlab International, participants tasked with solving complex puzzles while wearing biometric sensors experienced a staggering 65% drop in anxiety when 'Weightless,' originally released in 2014, played. 'Unlike most songs, it was composed in collaboration with sound therapists, with the [primary] purpose of slowing down the body's stress response,' Dr. Steven Allder, consulting neurologist at Re:Cognition Health, told Parade in a recent interview. The trippy tune starts at 60 beats per minute — the average resting heart rate — and gradually slows to 50, syncing with your body's rhythm like a lullaby for your nervous system. 'This subtle deceleration encourages a process known as entrainment, where the listener's heart rate and breathing naturally begin to match the tempo of the music, a physiological shift that supports relaxation,' Allder explained. 3 It's no shock this chill track 'Weightless' has become the anthem of relaxation — no pounding beats or sob stories here, just pure ear candy for the anxious soul. Moon Safari – It's no wonder the tune has become the poster child for musical stress relief. Unlike gym bangers or heartbreak ballads, this song goes easy on your eardrums. 'Weightless also features no sharp or abrupt transitions in rhythm, tone or volume,' Allder said. 'By avoiding these fluctuations, 'Weightless' maintains a constant auditory landscape, which promotes calm and reduces mental stimulation.' In other words: It's the anti-EDM. The 'Weightless' craze joins a growing body of research showing music can do everything from sharpen focus to soften pain — if you hit the right notes. For those looking to get in the zone rather than out of their head, neuroscientist Friederike Fabritius swears by Johann Sebastian Bach's 'Goldberg Variations.' 'When I have to focus, I always listen to [that] same song and I instantly get into flow,' Fabritius told Parade in a previous interview. Her hack: train your brain to associate one tune with deep work — Pavlov, meet Spotify. 3 Trying to focus, not freak out? Brain expert Friederike Fabritius says Bach's 'Goldberg Variations' hits the sweet spot for getting in the zone. Tomasz Zajda – Classical music is a smart bet for study tunes, Dr. Erin Hannon of the University of Nevada, Las Vegas, also told the outlet. She recommends tracks with 'a slow to moderate tempo, with moderately predictable pitch and rhythmic structure and lower levels of chaotic noise and dissonance, such as screaming.' Dr. Christina Agvent added in a previous study conducted by OnePoll on behalf of online university CSU Global that 'listening to music while studying can be an extremely helpful tool for some students in improving their focus,' especially among younger listeners — nearly 60% of Gen Z students say they plug in to study. And it's not just your mind that benefits. Music might also help turn down the volume on physical pain. In a recent McGill University study, participants reported lower pain levels when listening to tunes set to their own natural rhythm. So whether you're grinding through emails or gritting through aches, one thing's clear: the right beat can hit a lot harder than Advil. As Caroline Palmer of McGill put it, 'soothing or relaxing music works best as a pain reliever' — and tempo may be the secret sauce. Consider it doctor's orders: press play and chill out.
Yahoo
14 hours ago
- Yahoo
UT Health San Antonio researchers discover new links between heart disease and dementia
Research led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered new associations between various lipid, or fat, levels in the blood and the risk of developing Alzheimer's disease. SAN ANTONIO, May 30, 2025 /PRNewswire-PRWeb/ -- People who are at higher risk for heart disease also seem more likely to develop dementia. And research led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered new associations between various lipid, or fat, levels in the blood and the risk of developing Alzheimer's disease, the most common cause of dementia worldwide. The findings mean that using blood lipid profiles could help better understand, predict and possibly even prevent the disease in the future. In more than 800 older adults who were part of the long-running Framingham Heart Study, the researchers found that higher levels of small dense cholesterol particles – which are known to increase the risk of atherosclerosis and coronary heart disease – were associated with higher risk of developing Alzheimer's disease. However, higher levels of a marker for small fat-carrying particles, which are involved in the transport of dietary fats from the gut to other body tissues through the blood after eating, were associated with lower risk of developing the disease. Perhaps ironically, the researchers also discovered that individuals who had the lowest levels of highly dense cholesterol particles – often referred to as "good cholesterol" as it is considered protective against cardiovascular disease – had a lower risk of developing Alzheimer's disease compared to the rest of the included individuals. "These findings highlight the complex relationships of blood lipids with both heart and brain health, suggesting the possibility of certain blood lipids playing different roles in cardiovascular disease and dementia-related biological processes," said Sokratis Charisis, MD, a researcher with the Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases at UT Health San Antonio. Charisis is first author of the study published May 30 in the journal Neurology, titled, "Association of Blood Lipoprotein Levels With Incident Alzheimer's Disease in Community-Dwelling Individuals: The Framingham Heart Study." Other authors include corresponding author Sudha Seshadri, MD, director of the Biggs Institute, and researchers from Boston University School of Public Health, the University of Texas Rio Grande Valley and the Framingham Heart Study. A community-based analysis The new study notes that dementia is a leading source of morbidity and mortality in the aging population. Worldwide, there were 57.4 million people living with dementia in 2019, a number that is expected to reach 152.8 million by 2050. However, there is a general trend over time of decreasing incidence of Alzheimer's disease and other dementias in the U.S. and other higher-income countries that is at least partially attributed to better management of cardiovascular risk factors. The Framingham Heart Study is an ongoing, community-based cohort study that was launched in 1948 in Framingham, Massachusetts. Residents there ages 30 to 59 were randomly selected from census data to participate. Those with definite signs of cardiovascular disease at baseline were excluded. Participants of the original cohort have undergone up to 32 examinations performed every two years, which have included detailed history-taking by a physician, a physical examination and lab testing. The latest analysis by researchers led by UT Health San Antonio included participants from the original cohort who were 60 years or older and free of dementia during an examination period of 1985-1988, and had available cognitive follow-up and lipoprotein marker data. Lipoproteins act as a transport system for lipids in the bloodstream. Blood lipid levels and dementia Levels of high-density lipoprotein cholesterol (HDL-C), or good cholesterol; low-density lipoprotein cholesterol (LDL-C), or "bad cholesterol"; small dense LDL-C (sdLDL-C); and other lipoprotein types associated with heart disease were measured in blood samples obtained from the mid- to late-'80s examination period. The Framingham participants were watched for incident Alzheimer's disease, meaning a first diagnosis of the disease, until 2020. Of a total of 822 participants, 128 developed incident Alzheimer's disease. The researchers discovered that an increase of 1 standard deviation unit (SDU) of a concentration of small dense LDL-C (sdLDL-C), a value representing how far a specific data point deviates from the mean, was associated with a 21% increase in the risk for incident Alzheimer's disease. As the name implies, small dense LDL-C (sdLDL-C) is a type of the so-called bad cholesterol with smaller and denser particles than other low-density lipoproteins, and that is considered more likely to form plaque in arteries, strongly associated with an increased risk of atherosclerotic cardiovascular disease. A 1 SDU increase in a concentration of ApoB48, a lipoprotein that transports dietary fat from the intestines and into the bloodstream that also is tied to heart disease and cardiovascular problems, was found to be associated with a 22% decrease in the risk for incident Alzheimer's disease. Participants in the first quartile of HDL-C, or good cholesterol – in order of lesser amounts – were 44% less likely to develop Alzheimer's compared with those in the second, third and fourth quartiles. And those with small dense LDL-C concentrations below the median were 38% less likely to develop Alzheimer's compared with those with concentrations above the median. In summary, then, lower small-density bad cholesterol (sdLDL-C) concentrations and higher ApoB48 concentrations were associated with a lower Alzheimer's risk. And individuals with the lowest good cholesterol (HDL-C) concentrations were less likely to develop Alzheimer's compared with the remaining sample. "These findings underscore links between lipoprotein metabolism pathways and Alzheimer's risk, emphasizing the potential role of blood lipoprotein markers in Alzheimer's risk stratification and of lipid modification strategies in dementia prevention," the researchers concluded. Association of Blood Lipoprotein Levels With Incident Alzheimer's Disease in Community-Dwelling Individuals: The Framingham Heart Study Sokratis Charisis, Sophia Lu, Jesus David Melgarejo, Claudia L. Satizabal, Ramachandran S. Vasan, Alexa S. Beiser, Sudha Seshadri First published: May 30, 2025, in the journal Neurology Link to full study: The University of Texas Health Science Center at San Antonio (UT Health San Antonio), a primary driver of San Antonio's $44.1 billion health care and biosciences sector, is the largest academic research institution in South Texas with an annual research portfolio of more than $436 million. Driving substantial economic impact with its six professional schools, a diverse workforce of more than 9,400, an annual expense budget of $1.67 billion and clinical practices that provide 2.5 million patient visits each year, UT Health San Antonio plans continued growth over the next five years and anticipates adding more than 1,500 higher-wage jobs to serve San Antonio, Bexar County and the South Texas region. To learn about the many ways "We make lives better®," visit The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases is dedicated to providing comprehensive dementia care while advancing treatment through clinical trials and research. The Biggs Institute is a National Institute on Aging (NIA)-designated Alzheimer's Disease Research Center (ADRC). In addition to patient care and research, the Biggs Institute partners with the School of Nursing at UT Health Science Center San Antonio to offer the Caring for the Caregiver program. Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube. Media Contact Steven Lee, 2104503823, lees22@ View original content: SOURCE
